Dr Amy Burd speaks to ecancer at the ASH 2019 meeting in Orlando about results from the Beat AML master trial.
She reports that they achieved the primary endpoint of the study, with 94.7% of patients able to make a treatment decision within seven days.
Dr Burd also reports that there was a superior overall survival for patients treated within the Beat AML study compared to patients that were treated with standard of care.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content